These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Multicenter comparison of once-daily Uniphyl tablets administered in the morning or evening with baseline twice-daily theophylline therapy in patients with nocturnal asthma.
    Author: Grossman J.
    Journal: Am J Med; 1988 Jul 29; 85(1B):11-3. PubMed ID: 3041821.
    Abstract:
    Ninety-six patients with reversible airways disease and a history of nocturnal asthma completed a four-week open-label study that compared the effectiveness of Uniphyl tablets (The Purdue Frederick Company, Norwalk, Connecticut) administered once daily in the morning or the evening with twice-daily baseline theophylline therapy. All patients transferred easily from their previous twice-daily theophylline regimen to once-daily Uniphyl therapy. Predose serum theophylline levels and pulmonary function values were similar for the twice-daily and once-daily theophylline regimens. However, both the morning and evening once-daily Uniphyl regimens were judged by the investigators to control the asthmatic symptoms of more patients than did the prestudy twice-daily theophylline. In addition, patient acceptance of the two once-daily Uniphyl regimens was significantly (p less than 0.01) greater than that of the previous twice-daily theophylline therapy. During the fourth week of the study, the evening Uniphyl dosing schedule resulted in significantly (p less than 0.01) higher home-monitored morning peak expiratory flow rates and fewer nighttime awakenings than the pre-study twice-daily theophylline regimen. The morning regimen was not associated with such an improvement. The results of the study suggest that a once-daily evening dosage regimen with Uniphyl tablets provides greater control of nocturnal asthma.
    [Abstract] [Full Text] [Related] [New Search]